


PHARMACEUTICAL 2017



GYRE THERAPEUTICS INC. Rank 183 of 292





PHARMACEUTICAL 2017



GYRE THERAPEUTICS INC. Rank 183 of 292

The relative strengths and weaknesses of GYRE THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of GYRE THERAPEUTICS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 33% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	37,521
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,965
Liabilities, Non-Current	0
Other Assets	125
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	54
Other Net Income	3,872
Other Revenues	0
Property and Equipment	444
Research and Development	11,555
Selling, General and Administrative Expense	9,262

Output Variable	Value in 1000 USD
Assets	38,090
Liabilities	22,019
Expenses	20,817
Revenues	0
Stockholders Equity	16,071
Net Income	-16,945
Comprehensive Net Income	-16,946
Economic Capital Ratio	36%

